The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.
The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
National Institute of Neurology and Neurosurgery
Mexico City, Mexico City, Mexico
RECRUITINGHamilton Depression Rating Scale (HDRS) Score
Time frame: Change from baseline HDRS Score at 24 hours
Glutamate concentrations in the pregenual cingulate cortex (pgACC)
Glutamate concentrations in the pregenual cingulate cortex measured by Magnetic Resonance Spectroscopy
Time frame: Change from baseline Glutamate concentrations in the pgACC at 24 hours
Interleukin-1 (IL-1) and Tumoral Necrosis Factor-alpha (TNF-alpha) serum concentrations
Interleukin-1 and Tumoral Necrosis Factor-alpha concentrations in serum measured by ELISA
Time frame: Change from baseline IL-1 and TNF-alpha serum concentrations from baseline at 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.